BRPI0720383A2 - Derivados de 4-imidazolil-1,2,3,4-tetraidroquinolila e seu emprego como inibidores de aldosterona/11-beta-hidroxilase - Google Patents

Derivados de 4-imidazolil-1,2,3,4-tetraidroquinolila e seu emprego como inibidores de aldosterona/11-beta-hidroxilase

Info

Publication number
BRPI0720383A2
BRPI0720383A2 BRPI0720383-7A BRPI0720383A BRPI0720383A2 BR PI0720383 A2 BRPI0720383 A2 BR PI0720383A2 BR PI0720383 A BRPI0720383 A BR PI0720383A BR PI0720383 A2 BRPI0720383 A2 BR PI0720383A2
Authority
BR
Brazil
Prior art keywords
tetrahydroquinolyl
aldosterone
imidazolyl
derivatives
hydroxylase inhibitors
Prior art date
Application number
BRPI0720383-7A
Other languages
English (en)
Inventor
Qi-Ying Hu
Gary Michael Ksander
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0720383A2 publication Critical patent/BRPI0720383A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0720383-7A 2006-12-18 2007-12-14 Derivados de 4-imidazolil-1,2,3,4-tetraidroquinolila e seu emprego como inibidores de aldosterona/11-beta-hidroxilase BRPI0720383A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87049706P 2006-12-18 2006-12-18
PCT/US2007/087522 WO2008076860A1 (en) 2006-12-18 2007-12-14 4-imidazolyl-1,2,3,4-tetrahydroquinoline derivatives and their use as aldosterone/11-beta-hydroxylase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0720383A2 true BRPI0720383A2 (pt) 2015-06-16

Family

ID=39309674

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0720383-7A BRPI0720383A2 (pt) 2006-12-18 2007-12-14 Derivados de 4-imidazolil-1,2,3,4-tetraidroquinolila e seu emprego como inibidores de aldosterona/11-beta-hidroxilase

Country Status (11)

Country Link
US (1) US8143278B2 (pt)
EP (1) EP2121652A1 (pt)
JP (1) JP2010513558A (pt)
KR (1) KR20090090395A (pt)
CN (1) CN101605776A (pt)
AU (1) AU2007333902A1 (pt)
BR (1) BRPI0720383A2 (pt)
CA (1) CA2673119A1 (pt)
EA (1) EA200900812A1 (pt)
MX (1) MX2009006630A (pt)
WO (1) WO2008076860A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008076336A2 (en) 2006-12-18 2008-06-26 Novartis Ag Imidazoles as aldosterone synthase inhibitors
TW201006823A (en) * 2008-07-14 2010-02-16 Novartis Ag Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
EP2594557B1 (en) 2009-05-28 2016-08-10 Novartis AG Substituted aminopropionic derivatives as neprilysin inhibitors
MX2011012627A (es) 2009-05-28 2011-12-14 Novartis Ag Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
CN102711916B (zh) * 2010-01-14 2015-09-02 诺华股份有限公司 肾上腺激素调节剂的用途
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
TWI627167B (zh) 2011-07-08 2018-06-21 諾華公司 用於高三酸甘油酯個體治療動脈粥狀硬化之方法
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
CN105073762B (zh) 2013-02-14 2017-03-08 诺华股份有限公司 作为nep(中性内肽酶)抑制剂的取代的联苯丁酰膦酸衍生物
RU2015137972A (ru) 2013-03-08 2017-04-13 Ф. Хоффманн-Ля Рош Аг Новые производные дигидрохинолин-2-она в качестве ингибиторов альдостеронсинтазы (cyp1 1 b2 или cyp1 1 b1)
UY35671A (es) 2013-07-25 2015-02-27 Novartis Ag Bioconjugados de polipéptidos de apelina sintética
EP3024845A1 (en) 2013-07-25 2016-06-01 Novartis AG Cyclic polypeptides for the treatment of heart failure
JP2015110563A (ja) * 2013-11-08 2015-06-18 日本メジフィジックス株式会社 アルドステロン合成酵素阻害剤
SG11201704758XA (en) 2015-01-23 2017-08-30 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
CN104774884A (zh) * 2015-04-14 2015-07-15 遵义医学院 一种具有光学活性的组合物
CN104774177A (zh) * 2015-04-14 2015-07-15 遵义医学院 一种具有光学活性的多环苄醇衍生物
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
EP3887363A1 (en) 2018-11-27 2021-10-06 Novartis AG Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
CN113166204A (zh) 2018-11-27 2021-07-23 诺华股份有限公司 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状肽
CN112079826B (zh) * 2020-09-17 2022-07-29 广州中医药大学(广州中医药研究院) 一类甾体合成酶抑制剂及其治疗应用
TW202333563A (zh) 2021-11-12 2023-09-01 瑞士商諾華公司 用於治療疾病或障礙之二胺基環戊基吡啶衍生物
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8320184D0 (en) * 1983-07-27 1983-09-01 Beecham Group Plc Compounds
NZ219311A (en) * 1986-02-27 1989-04-26 Janssen Pharmaceutica Nv Imidazoles and herbicidal compositions
US6777427B2 (en) * 2000-09-14 2004-08-17 Kaken Pharmaceutical Co., Ltd. Tetrahydroquinoline compounds
DE102004035322A1 (de) 2004-07-21 2006-02-16 Universität des Saarlandes Selektive Hemmstoffe humaner Corticoidsynthasen
BRPI0709678A2 (pt) * 2006-03-29 2011-07-19 Novartis Ag compostos orgánicos
WO2008076336A2 (en) 2006-12-18 2008-06-26 Novartis Ag Imidazoles as aldosterone synthase inhibitors
EP2094669A2 (en) 2006-12-18 2009-09-02 Novartis AG 1-substituted imidazole derivatives and their use as aldosterone synthase inhibitors

Also Published As

Publication number Publication date
KR20090090395A (ko) 2009-08-25
EA200900812A1 (ru) 2009-12-30
CN101605776A (zh) 2009-12-16
EP2121652A1 (en) 2009-11-25
CA2673119A1 (en) 2008-06-26
WO2008076860A1 (en) 2008-06-26
US8143278B2 (en) 2012-03-27
MX2009006630A (es) 2009-06-30
US20100093711A1 (en) 2010-04-15
JP2010513558A (ja) 2010-04-30
AU2007333902A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
BRPI0720383A2 (pt) Derivados de 4-imidazolil-1,2,3,4-tetraidroquinolila e seu emprego como inibidores de aldosterona/11-beta-hidroxilase
BRPI0911444A2 (pt) benzoimidazóis como inibidores de prolil hidroxilase
BRPI0820236A2 (pt) Derivados de piridazinona como inibidores parp
BRPI0810679A2 (pt) Derivados de 4-aza indol e seu uso como fungicidas
DE602007010981D1 (de) Cycloalkylaminsubstituierte isochinolin- und isochinolinonderivate
DK1981889T3 (da) Cytotoksiske midler, der omfatter nye tomaymycin-derivater, og terapeutisk anvendelse deraf
BRPI0719991A2 (pt) Derivados de di-hidropiridina úteis como inibidores de proteína cinase
ATE525374T1 (de) Heteroarylsubstituierte pyrroloä2,3-büpyridine und pyrroloä2,3-büpyrimidine als januskinaseinhibitoren
IL210412A0 (en) Heterocyclic derivatives and uses thereof
BRPI0922095A2 (pt) derivados de piridina e pirimidina como inibidores de fosfodiesterase 10
BRPI0820544A2 (pt) 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase
BRPI0810858A2 (pt) Derivados de 2-heteroaril-pirrolo[3,4-c] pirrol e seus usos como inibidores de scd
EP2264017A4 (en) Heterocyclic derivative and its use
HK1135983A1 (en) Multi-substituted pyridyl sulfoximines and their use as insecticides
DK2170890T3 (da) Cytotoksiske midler, der omfatter nye tomaymycin-derivater, og terapeutisk anvendelse deraf
BRPI0921598A2 (pt) derivados de piridina e pirimidina como inibidores de fosfodiesterase 10
IL186112A0 (en) SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND Pak INHIBITORS
ATE549340T1 (de) Spiroindolinon-derivate als mdm2-p53 inhibitoren
DE602007006535D1 (de) Diazepan-acetamidderivate als selektive 11-hsd1-hemmer
BRPI0920183A2 (pt) derivados de fenetilamida e seus analogos heterociclicos
CR10879A (es) Cyclized derivatives as eg-5 inhibitors
HK1131747A1 (en) Cycloalkanopyrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors
ATE545417T1 (de) Pyrazoloä3,4-büpyridin-derivate als phosphodiesterasehemmer
BRPI0816806A2 (pt) Derivados de azaciclil-isoquinolinona e isoindolinona como antagonista de histamina-3
CR10039A (es) Derivados espirocíclicos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.